Form 4: Teladoc Health Executive Andrew Turitz Reports Stock Transactions
SEC Form 4
EVP Andrew Turitz of Teladoc Health reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, through both market sales and vesting events.
Summary
- Andrew Turitz, EVP of Corporate Development at Teladoc Health, filed a Form 4 detailing changes in beneficial ownership of company stock.
- On March 1, 2024, Turitz sold 475 shares of common stock at $15.06 per share and acquired shares through the vesting of performance stock units (4,226, 437, 867) and restricted stock units (1,348, 12,400, 1,148).
- On March 1, 2024, Turitz was also granted 12,679 performance stock units based on the company's 2023 financial results, vesting one-third immediately and the remainder in quarterly installments.
- On March 4, 2024, Turitz sold 6,190 shares at $14.516 to cover tax obligations related to the vesting of stock units.
- Following these transactions, Turitz directly owns 39,429 shares of Teladoc Health common stock and various performance and restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The document primarily reports stock transactions related to vesting and tax obligations, with no explicit positive or negative implications for the company's performance.
Positives
- The vesting of performance stock units suggests that the company met certain performance metrics related to its 2023 financial results.
Negatives
- The sale of shares by an executive could be interpreted negatively by some investors, although the sales appear to be related to tax obligations and a pre-arranged trading plan.
Risks
- Executive stock sales could create short-term downward pressure on the stock price.
- The vesting of performance stock units is contingent on continued employment and the achievement of future performance metrics.
Future Outlook
The performance stock units vest over time, contingent on continued employment and potentially future performance metrics.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's confidence in the company's future prospects.
Comparison to Industry Standards
- Comparing Teladoc's executive compensation and stock ownership to peers like Amwell (AMWL) and similar telehealth companies can provide context.
- Analyzing the vesting schedules and performance metrics associated with stock grants against industry benchmarks can reveal if Teladoc's incentives are aligned with shareholder value creation.
- Reviewing insider trading activity relative to other companies in the healthcare technology sector can offer insights into market sentiment.
Stakeholder Impact
- Shareholders may be interested in executive stock transactions as an indicator of management's confidence.
- Employees holding stock options or restricted stock units may be affected by the stock price fluctuations resulting from these transactions.
Next Steps
- Monitor future Form 4 filings by Teladoc Health executives for further insights into their stock ownership and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2021-03-02 | Andrew Turitz was granted 3,442 restricted stock units, vesting in three equal annual installments. |
| 2022-03-01 | Andrew Turitz was granted 16,170 restricted stock units, vesting one-third on the first anniversary and the remainder in quarterly installments. |
| 2022-03-02 | Andrew Turitz earned 2,602 performance stock units, vesting in three equal annual installments. |
| 2023-03-02 | Andrew Turitz earned 874 performance stock units, vesting in two equal annual installments. |
| 2023-03-03 | Andrew Turitz was granted 37,202 restricted stock units, vesting one-third on March 1, 2024, and the remainder in quarterly installments. |
| 2023-11-27 | The reporting person adopted a Rule 10b5-1 trading plan. |
| 2024-03-01 | Various transactions occurred, including sales, vesting of performance stock units and restricted stock units, and the grant of new performance stock units. |
| 2024-03-04 | Andrew Turitz sold 6,190 shares at $14.516 to cover tax obligations. |
| 2024-03-05 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.